Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Mon, 27.09.2021
Formycon AG
Press Release // September 27, 2021
Formycon Reports on Virtual Annual General Meeting 2021
- Shareholders approve all items on the agenda
- Management Board reports in detail on ongoing development projects
- Supervisory Board and Management Board ratified by a large majority
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its [ … ]
Thu, 23.09.2021
Formycon
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes stuft die Aktie auf BUY
herauf und bestätigt sein Kursziel von EUR 78,00.
Zusammenfassung:
Die Umsatzerlöse in H1/21 in Höhe von €20,3 Mio. (FBe €21,0 Mio.; H1/20:
€16,5 Mio.) lagen nah [ … ]
Tue, 21.09.2021
Formycon AG
Press Release // September 21, 2021
Formycon Publishes Half-Year Results for 2021
- Group turnover above H1 half-year level at Euro 20.3 million
- EBITDA of Euro -9.7 million and half-year results of Euro -10.2 million in line with plans
- Result due to investments in the non-partnered projects FYB206 and FYB207
- Significant progress in th [ … ]
Wed, 15.09.2021
Formycon AG
Press Release // September 15, 2021
Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug developme [ … ]
Wed, 11.08.2021
Formycon AG
Press Release // August 11, 2021
Formycon reports on the status of FYB207 development
- Efficient neutralization of SARS-CoV-2 variants-of-concern
- Production for preclinical and clinical product established at fast track
- Expansion of preclinical efficacy testing planned
- Phase I/IIa clinical trial expected to start first half of 2022
[ … ]
Thu, 05.08.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 5, 2021
Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)
Munich - Formyco [ … ]
Mon, 12.07.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // July 12, 2021
Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A [ … ]
Mon, 05.07.2021
Formycon
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes stuft die Aktie auf ADD
herab und bestätigt sein Kursziel von EUR 78,00.
Zusammenfassung:
Im vergangenen November gab Formycon bekannt, dass sie die BLA (Biologics
License Application) für ihr Lucentis-Bio [ … ]
Wed, 30.06.2021
Formycon AG
Press Release // June 30, 2021
Formycon Reports Financial Results for the First Quarter of 2021
- Sales and other earnings total EUR 9.4 million
- EBITDA is EUR -1.7 million
- EBIT and net result in line with expectations at around EUR -2.0 million each
Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today presented the sales and ea [ … ]
Tue, 29.06.2021
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 29, 2021
Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA)
Munich - Formycon AG (ISI [ … ]